Physician profile
Todd Bouchier
NPI 1316132442
$3,248.71
in general payments reported to CMS, 2019-2025
32 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $459 · 2021: $279 · 2022: $357 · 2023: $475 · 2024: $477 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $470.56 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $374.08 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $301.15 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $293.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.95 | 2020-2025 | Jardiance, Ofev |
| Neurocrine Biosciences, INC. | $177.44 | 2022-2024 | Ingrezza |
| Exact Sciences Corporation | $157.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $145.13 | 2019-2024 | Repatha, Otezla, Prolia |
| E.R. Squibb & Sons, L.L.C. | $123.27 | 2022-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $116.99 | 2025 | Diamondback Peripheral |
| Astrazeneca Pharmaceuticals LP | $106.33 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $91.83 | 2019-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $76.25 | 2022 | |
| Abbvie INC. | $64.39 | 2023-2025 | Linzess, Viberzi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.49 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $41.00 | 2025 | |
| Abiomed | $38.06 | 2025 | |
| Merck Sharp & Dohme LLC | $35.58 | 2019-2024 | Dificid |
| Idorsia Pharmaceuticals US INC | $31.57 | 2023 | Quviviq |
| Amarin Pharma, INC. | $29.07 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $26.53 | 2021 | |
| Sun Pharmaceutical Industries INC. | $23.44 | 2021 | |
| Hologic Sales and Service, LLC | $23.04 | 2025 | Aptima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.95 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $21.09 | 2021 | |
| Acadia Pharmaceuticals INC | $19.98 | 2020 | |
| Therapeuticsmd, INC. | $14.68 | 2019 | |
| Eisai INC. | $13.68 | 2020 | |
| Collegium Pharmaceutical, INC. | $13.09 | 2021 | |
| Alfasigma USA, INC. | $12.97 | 2021 | |
| Medtronic Vascular, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bouchier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.